Measuring the impact of rare diseases in Tasmania, Australia.
Costs
Data linkage analysis
Inpatient admissions
Rare diseases
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
20
05
2024
accepted:
27
08
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
An ongoing challenge with rare diseases is limited data and, consequently, limited knowledge about the collective prevalence and impact of these conditions on individuals, families, and the health system, particularly in rural and regional areas. Using existing datasets, this project aimed to examine the epidemiology of and hospital activity for Tasmanians with rare diseases. Rare diseases were defined as non-infectious diseases with a prevalence of less than 1 in 2000. An initial resource set of 1028 ICD-10-AM diagnostic codes was used to identify a cohort of Tasmanians with rare diseases in Tasmanian Health datasets (1 January 2007 until 31 December 2020). Validating the resource set using a small group with known rare diseases revealed limitations in ascertainment, and so an expanded set of 1940 ICD-10-AM diagnostic codes was developed by cross-referencing ICD-10-AM codes with Orphanet data. Cohort hospital activity and admission costs were compared to statewide data for the final year of the study, 01 January 2020 to 31 December 2020. Using the resource set of 1028 ICD-10-AM diagnostic codes, the period prevalence of rare diseases in Tasmania across all age groups was estimated at 3.5%, with a point prevalence of 1.5% in December 2020. In 2020, 3384 individuals within the Tasmanian rare disease cohort, representing 0.6% of the Tasmanian population, accessed the public hospital system and accounted for 5.6% of all admissions. The mean length of stay for rare disease-related hospital admissions was 5.0 days, compared to 3.3 days for non-rare disease-related admissions. The mean cost per admission for the rare disease cohort was AUD$11,310, compared to AUD$6475 for all admissions statewide. In 2020, using the expanded resource set, the total cost of public hospital admissions in Tasmania was estimated to be AUD$979 million, with rare disease-related hospital admissions accounting for 9.1% of this cost, increasing to 19.0% when the costs for all admissions for the rare disease patients were included. Patients with rare diseases had more admissions, longer length of stay, and a higher average cost per admission. Patients with rare diseases have a disproportionate impact on statewide hospital activity and costs in Tasmania.
Sections du résumé
BACKGROUND
BACKGROUND
An ongoing challenge with rare diseases is limited data and, consequently, limited knowledge about the collective prevalence and impact of these conditions on individuals, families, and the health system, particularly in rural and regional areas. Using existing datasets, this project aimed to examine the epidemiology of and hospital activity for Tasmanians with rare diseases.
METHODS
METHODS
Rare diseases were defined as non-infectious diseases with a prevalence of less than 1 in 2000. An initial resource set of 1028 ICD-10-AM diagnostic codes was used to identify a cohort of Tasmanians with rare diseases in Tasmanian Health datasets (1 January 2007 until 31 December 2020). Validating the resource set using a small group with known rare diseases revealed limitations in ascertainment, and so an expanded set of 1940 ICD-10-AM diagnostic codes was developed by cross-referencing ICD-10-AM codes with Orphanet data. Cohort hospital activity and admission costs were compared to statewide data for the final year of the study, 01 January 2020 to 31 December 2020.
RESULTS
RESULTS
Using the resource set of 1028 ICD-10-AM diagnostic codes, the period prevalence of rare diseases in Tasmania across all age groups was estimated at 3.5%, with a point prevalence of 1.5% in December 2020. In 2020, 3384 individuals within the Tasmanian rare disease cohort, representing 0.6% of the Tasmanian population, accessed the public hospital system and accounted for 5.6% of all admissions. The mean length of stay for rare disease-related hospital admissions was 5.0 days, compared to 3.3 days for non-rare disease-related admissions. The mean cost per admission for the rare disease cohort was AUD$11,310, compared to AUD$6475 for all admissions statewide. In 2020, using the expanded resource set, the total cost of public hospital admissions in Tasmania was estimated to be AUD$979 million, with rare disease-related hospital admissions accounting for 9.1% of this cost, increasing to 19.0% when the costs for all admissions for the rare disease patients were included.
CONCLUSIONS
CONCLUSIONS
Patients with rare diseases had more admissions, longer length of stay, and a higher average cost per admission. Patients with rare diseases have a disproportionate impact on statewide hospital activity and costs in Tasmania.
Identifiants
pubmed: 39468681
doi: 10.1186/s13023-024-03343-2
pii: 10.1186/s13023-024-03343-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
399Subventions
Organisme : Royal Hobart Hospital Research Foundation
ID : 21-209
Informations de copyright
© 2024. Crown.
Références
EURORDIS. Rare Diseases: Understanding this Public Health Priority. 2005. https://www.eurordis.org/wp-content/uploads/2009/12/princeps_document-EN.pdf . Accessed 01 Jun 2023.
Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, et al. How many rare diseases are there? Nat Rev Drug Discov. 2020;19(2):77–8.
doi: 10.1038/d41573-019-00180-y
pubmed: 32020066
pmcid: 7771654
Elliott E, Zurynski Y. Rare diseases are a ‘common’ problem for clinicians. Aust Fam Phys. 2015;44(9):630–3.
Walker CE, Mahede T, Davis G, Miller LJ, Girschik J, Brameld K, et al. The collective impact of rare diseases in Western Australia: an estimate using a population-based cohort. Genet Med. 2017;19(5):546–52.
doi: 10.1038/gim.2016.143
pubmed: 27657686
Zurynski Y, Deverell M, Dalkeith T, Johnson S, Christodoulou J, Leonard H, et al. Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays. Orphanet J Rare Dis. 2017;12(1):68.
doi: 10.1186/s13023-017-0622-4
pubmed: 28399928
pmcid: 5387276
Molster C, Urwin D, Di Pietro L, Fookes M, Petrie D, van der Laan S, et al. Survey of healthcare experiences of Australian adults living with rare diseases. Orphanet J Rare Dis. 2016;11(1):30.
doi: 10.1186/s13023-016-0409-z
pubmed: 27012247
pmcid: 4806449
Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–73.
doi: 10.1038/s41431-019-0508-0
pubmed: 31527858
Hong Kong Genome Project, Chung CCY, Chu ATW, Chung BHY. Rare disease emerging as a global public health priority. Front Public Health. 2022. https://doi.org/10.3389/fpubh.2022.1028545 .
doi: 10.3389/fpubh.2022.1028545
pmcid: 9632971
Commonwealth of Australia, Department of Health. The National Strategic Action Plan for Rare Disease. 2020. https://www.health.gov.au/sites/default/files/documents/2020/03/national-strategic-action-plan-for-rare-diseases.pdf . Accessed 16 Aug 2022.
Ward MM. Estimating rare disease prevalence from administrative hospitalization databases. Epidemiology. 2005;16(2):270–1.
doi: 10.1097/01.ede.0000153643.88019.92
pubmed: 15703546
Mazzucato M, Pozza LVD, Facchin P, Angin C, Agius F, Cavero-Carbonell C, et al. ORPHAcodes use for the coding of rare diseases: comparison of the accuracy and cross country comparability. Orphanet J Rare Dis. 2023;18(1):267.
doi: 10.1186/s13023-023-02864-6
pubmed: 37667299
pmcid: 10476382
Aymé S, Bellet B, Rath A. Rare diseases in ICD11: making rare diseases visible in health information systems through appropriate coding. Orphanet J Rare Dis. 2015;10(1):35.
doi: 10.1186/s13023-015-0251-8
pubmed: 25887186
pmcid: 4377208
Australian Institute of Health and Welfare. ICD-11 frequently asked questions and resources. https://www.aihw.gov.au/about-us/international-collaboration/australian-collaborating-centre-for-who/icd-11/faq-resources . Accessed 15 Jan 2024.
Chiu ATG, Chung CCY, Wong WHS, Lee SL, Chung BHY. Healthcare burden of rare diseases in Hong Kong–adopting ORPHAcodes in ICD-10 based healthcare administrative datasets. Orphanet J Rare Dis. 2018;13(1):147.
doi: 10.1186/s13023-018-0892-5
pubmed: 30153866
pmcid: 6114034
Gunne E, Lambert DM, Ward AJ, Murphy DN, Treacy EP, Lynch SA. An estimate of the cumulative paediatric prevalence of rare diseases in Ireland and comment on the literature. Eur J Hum Genet. 2022;30(11):1211–5.
doi: 10.1038/s41431-022-01144-4
pubmed: 35853949
pmcid: 9626478
Baldacci S, Santoro M, Pierini A, Mezzasalma L, Gorini F, Coi A. Healthcare burden of rare diseases: A population-based study in Tuscany (Italy). IJERPH. 2022;19(13):7553.
doi: 10.3390/ijerph19137553
pubmed: 35805212
pmcid: 9265803
Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, Kennedy A. The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. 2022;17(1):163.
doi: 10.1186/s13023-022-02299-5
pubmed: 35414039
pmcid: 9004040
Tasmanian Department of Health. The State of Public Health Tasmania 2018. Tasmanian Government. 2019. https://www.health.tas.gov.au/sites/default/files/2022-03/The_State_of_Public_Health_Tasmania_2018_DoHTasmania2018.pdf . Accessed 15 Mar 2024.
Primary Health Tasmania. Primary Health Tasmania Health Needs Assessment 2022–23 To 2024–25. In Health in Tasmania. 2021. https://www.primaryhealthtas.com.au/wp-content/uploads/2022/04/Primary-Health-Tasmania-Needs-Assessment-2022-25.pdf . Accessed 15 Mar 2024.
Stokes B, Wiggins N, Albion T, Venn A. Tasmanian data linkage unit: supporting innovative research, planning and policy formulation in Australia through the provision of high-quality linked-data services. IJPDS. 2020;4(2):09.
doi: 10.23889/ijpds.v4i2.1137
Australian Bureau of Statistics. Population - states and territories. In: National, state and territory population. 2022. https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/jun-2023/310104.xlsx . Accessed 14 Oct 2022.
Independent Health and Aged Care Pricing Authority (IHACPA). ICD-10 and ICD-10-AM mapping table. In: ICD-10-AM and ACHI mapping tables. 2022. https://www.ihacpa.gov.au/sites/default/files/2022-12/ICD-10%20and%20ICD-10-AM%20mapping%20tables%20-%20Twelfth%20Edition.XLSX . Accessed 16 Mar 2023.
Independent Health and Aged Care Pricing Authority (IHACPA). Supplementary codes for chronic conditions map to ICD-10-AM Eleventh Edition. In: ICD-10-AM and ACHI mapping tables. 2022. https://www.ihacpa.gov.au/sites/default/files/2022-08/supplementary_codes_for_chronic_conditions_map_to_icd-10-am_eleventh_edition.xlsx . Accessed 24 Mar 2023.
Independent Health and Aged Care Pricing Authority (IHACPA). The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM) Chronicle, First Edition to Twelfth Edition, Part 1: A00–T98, Z00–Z99. 2022. https://www.ihacpa.gov.au/sites/default/files/2022-12/ICD-10-AM%20Chronicle_Twelfth%20Edition_Part%201_A00%20to%20T98%20and%20Z00%20to%20Z99.PDF . Accessed 30 Mar 2023.
Orphadata. Rare diseases and alignment with ICD-10, ICD-11, OMIM, UMLS, MeSH, MedDRA and GARD. In: Rare Diseases and Alignment with Terminologies and Databases. Orphanet Knowledge Base. 2023. https://www.orphadata.com/alignments/ . Accessed 02 Mar 2023.
RARECAREnet List of Rare Cancers. In: Cancer List. Information Network on Rare Cancers. 2015. https://www.rarecarenet.eu/rarecarenet/images/Resources/RARECAREnet_list_of_rare_cancers_Dec15.xlsx . Accessed 12 May 2023.
Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47(17):2493–511.
doi: 10.1016/j.ejca.2011.08.008
pubmed: 22033323
Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 2017;18(8):1022–39.
doi: 10.1016/S1470-2045(17)30445-X
pubmed: 28687376
Orphanet. Orphadata: Free access products description. 2020. https://www.orphadata.com/docs/OrphadataFreeAccessProductsDescription.pdf . Version 2. Accessed 02 Mar 2023.
Rath A, Olry A, Dhombres F, Brandt MM, Urbero B, Ayme S. Representation of Rare Diseases in Health Information Systems: The Orphanet Approach to Serve a Wide Range of End Users. Hum Mutat. 2012;33(5):803–8.
doi: 10.1002/humu.22078
pubmed: 22422702
Orphanet. Linearisation rules for rare diseases. In: Orphanet procedural document. Reports collection. 2014. http://www.orpha.net/orphacom/cahiers/docs/GB/Orphanet_linearisation_rules.pdf . Accessed 12 Nov 2021.
Orphanet. Procedural document on the Orphanet nomenclature and classification of rare diseases. 2020. Number 02. https://www.orpha.net/pdfs/orphacom/cahiers/docs/GB/eproc_disease_inventory_R1_Nom_Dis_EP_04.pdf . Accessed 12 Nov 2021.
Independent Health and Aged Care Pricing Authority (IHACPA). AR-DRG Version 11.0 (2023). https://www.ihacpa.gov.au/resources/ar-drg-version-110 . Accessed 01 Feb 2024.
Australian Institute of Health and Welfare. Data Tables: Health expenditure Australia 2021–22, Table 39. 2023. https://www.aihw.gov.au/reports/health-welfare-expenditure/health-expenditure-australia-2021-22/data . Accessed 26 Apr 2024.
Tisdale A, Cutillo CM, Nathan R, Russo P, Laraway B, Haendel M, et al. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. Orphanet J Rare Dis. 2021;16(1):429.
doi: 10.1186/s13023-021-02061-3
pubmed: 34674728
pmcid: 8532301
Australian Institute of Health and Welfare. Australian Burden of Disease Study: Methods and supplementary material 2018. 2021. https://www.aihw.gov.au/reports/burden-of-disease/abds-methods-supplementary-material-2018/contents/2-overarching-methods-and-choices/overarching-methods-and-choices-for-abds-2018#ICD . Accessed 15 Mar 2024.
Australian Institute of Health and Welfare. Health system spending on disease and injury in Australia, 2020–21. 2023. https://www.aihw.gov.au/reports/health-welfare-expenditure/health-system-spending-on-disease-and-injury-in-au/contents/australian-burden-of-disease-groups . Accessed 15 Mar 2024.
Navarrete-Opazo AA, Singh M, Tisdale A, Cutillo CM, Garrison SR. Can you hear us now? The impact of health-care utilization by rare disease patients in the United States. Genet Med. 2021;23(11):2194–201.
doi: 10.1038/s41436-021-01241-7
pubmed: 34183788
pmcid: 8553605
Stark Z, Schofield D, Martyn M, Rynehart L, Shrestha R, Alam K, et al. Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness. Genet Med. 2019;21(1):173–80.
doi: 10.1038/s41436-018-0006-8
pubmed: 29765138
Yeung A, Tan NB, Tan TY, Stark Z, Brown N, Hunter MF, et al. A cost-effectiveness analysis of genomic sequencing in a prospective versus historical cohort of complex pediatric patients. Genet Med. 2020;22(12):1986–93.
doi: 10.1038/s41436-020-0929-8
pubmed: 32773771
Ruseckaite R, Mudunna C, Caruso M, Helwani F, Millis N, Lacaze P, et al. Current state of rare disease registries and databases in Australia: a scoping review. Orphanet J Rare Dis. 2023;18(1):216.
doi: 10.1186/s13023-023-02823-1
pubmed: 37501152
pmcid: 10373259